AstraZeneca Plc (LSE:AZ), a global, science-led biopharmaceutical company, announced on Friday that with the company's agreement, Joseph G. Peter (Joe Peter) has withdrawn his candidacy as a Non-Executive Director (NED) and a member of the audit committee.
The company said Peter's proposed appointment to these positions was announced on 6 September 2018 and was to have become effective on 1 October 2018.
According to AstraZeneca, Peter's reasons for the decision are not related to the company.
AstraZeneca focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in the three therapy areas of Oncology, Cardiovascular, Renal & Metabolism and Respiratory.
AstraZeneca invests USD300m to expand US manufacturing for cell therapy
Innovent Biologics announces CFO transition
Cardio Diagnostics appoints Dr Vimal Ramjee as Strategic Advisor
Acticor Biotech reports positive ACTIMIS clinical study results in Lancet Neurology Journal